放疗联合免疫检查点抑制剂在实体瘤中的生存影响:随机对照试验的系统综述与动态Meta分析
该系统综述与动态Meta分析纳入41项随机试验共15,049例实体瘤患者,评估放疗联合免疫检查点抑制剂(ICI)对比单用放疗或ICI的生存影响。在ICI试验中,总生存(OS)汇总HR为0.88(95%CI 0.75-1.02),排除胶质母细胞瘤试验后达统计学显著(HR 0.83,95%CI 0.70-0.99);无进展生存(PFS)和事件无生存(EFS)汇总HR分别为0.80(95%CI 0.68-0.93)和0.73(95%CI 0.55-0.99)。辅助ICI较同步/诱导ICI带来更大OS和PFS获益。
要点
- 放疗基础上加ICI改善PFS/EFS,排除胶质母细胞瘤后OS获益显著。
- 辅助序贯ICI较同步/诱导ICI的OS和PFS获益更优,交互作用显著。
- 肿瘤类型异质性明显,胶质母细胞瘤可能稀释OS获益。
核心结论
- 放疗基础上加ICI改善PFS和EFS,排除胶质母细胞瘤试验后OS获益达统计学显著,提示肿瘤特异性异质性。
- ICI的时序安排关键,辅助ICI较同步/诱导ICI带来更大OS和PFS获益。
研究设计与样本
- 动态系统综述与Meta分析,检索PubMed和EMBASE(2010年1月至2026年1月)的随机对照试验。
- 共纳入41项试验15,049例患者:35项为ICI对比无ICI,6项为放疗对比无放疗。
- 采用RoB-2评估偏倚风险,随机效应模型汇总OS、PFS、EFS的风险比(HR),Meta回归探索亚组效应。
主要发现
- ICI试验中OS汇总HR为0.88(95%CI 0.75-1.02;n=28),排除胶质母细胞瘤试验后为0.83(95%CI 0.70-0.99;n=23)。
- ICI试验中PFS汇总HR为0.80(95%CI 0.68-0.93;n=27),EFS汇总HR为0.73(95%CI 0.55-0.99;n=7)。
- 辅助ICI对比同步/诱导ICI的OS汇总HR为0.81 vs 0.98(交互作用p=0.045),PFS汇总HR为0.69 vs 0.94(交互作用p=0.013)。
临床怎么用
- 在放疗基础上联合ICI可改善PFS/EFS,排除胶质母细胞瘤后OS获益显著。
- 优先考虑辅助序贯ICI而非同步/诱导ICI,以最大化OS和PFS获益。
- 需结合肿瘤类型评估联合策略,胶质母细胞瘤可能不获益。
局限性
- OS汇总HR在整体ICI试验中未达统计学显著,需排除胶质母细胞瘤试验后方显著。
- 放疗对比无放疗的随机试验仅6项,证据有限。
- Meta分析基于试验水平汇总,可能存在亚组间异质性未完全解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies indicate synergistic effects of radiotherapy and immune checkpoint inhibitors (ICIs), yet randomized trials have yielded inconsistent results. We conducted a living systematic review and meta-analysis to evaluate the survival impact of combining radiotherapy with ICIs versus radiotherapy or ICIs alone in solid tumors. METHODS: PubMed and EMBASE were searched for randomized trials (January 2010-January 2026), evaluating two strategies: (1) addition of ICIs to a radiotherapy backbone (immunotherapy trials), and (2) addition of radiotherapy to an ICI backbone (radiotherapy trials). Risk of bias was assessed with RoB-2. Hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) were pooled using random-effects models. Meta-regression explored subgroup effects. RESULTS: Of 4447 unique records, 41 trials (15,049 patients) were included: 35 ICIs versus no ICIs and 6 radiotherapy versus no radiotherapy trials. Methodological quality was high. Across ICI trials, the pooled HR for OS was 0.88 (95%CI 0.75-1.02; n = 28), reaching statistical significance after exclusion of glioblastoma trials (pooled HR 0.83, 95%CI 0.70-0.99; n = 23). For PFS and EFS, pooled HRs were 0.80 (95%CI 0.68-0.93; n = 27) and 0.73 (95%CI 0.55-0.99; n = 7), respectively. Adjuvant ICIs conferred greater benefit than concurrent/induction for OS (pooled HR 0.81 versus 0.98; interaction p = 0.045) and PFS (pooled HR 0.69 versus 0.94; interaction p = 0.013). CONCLUSIONS: This meta-analysis provides a field-wide overview of randomized trials on combining radiotherapy and ICIs. Addition of ICIs to a radiotherapy backbone improves PFS/EFS and yields an OS benefit after exclusion of glioblastoma trials, highlighting tumor-specific heterogeneity. Sequencing appears critical, with greatest benefit observed for adjuvant ICIs. The living meta-analysis is available at https://www.immunorad.org/clinical-evidence.
引用
- Tomassen ML, Pronk CE, Deutsch E, et al. The survival impact of combining radiotherapy and immune checkpoint inhibitors in patients with solid tumors: A systematic review and living meta-analysis of randomized controlled trials. Eur J Cancer. 2026. PMID: 42208279. doi:10.1016/j.ejca.2026.116820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。